Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trospium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 11/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.97 |
| ▸ | HRH1 | P35367 | 3/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trospium SCHEMBL13836646 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL29389006 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL111738 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL29629492 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL119810 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL2447242 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL724191 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL31112961 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL22609933 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL1707994 | 0.94 | CHRM3 (0.89) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3712 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3646870-B1 | COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | PureTech Health LLC (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122036720-A | Synthesis method of key intermediate of trospium chloride | 山东新时代药业有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122036719-A | Oxygen-mediated trospium chloride key intermediate microchannel synthesis method | 山东新时代药业有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4729060-A2 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARNIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260102350-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | KARUNA THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | claimed |
| US-12558317-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | Karuna Therapeutics, Inc. (US) | 2026-02-24 | — | — | US | claimed |
| EP-4692084-A1 | NOVEL DERIVATIVES OF N-SUBSTITUTED NORTROPINONE, THEIR PRODUCTION AND THEIR USE | Siegfried AG (CH) | 2026-02-11 | — | — | EP | claimed |
| EP-3856182-B1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARNIC RECEPTOR ACTIVATION | KARUNA THERAPEUTICS INC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250228832-A1 | METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2025-07-17 | — | — | US | claimed |
| CN-115667235-B | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | 卡鲁娜治疗学有限公司 | 2025-06-17 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5998430-A | Use of trospium chloride and 2-component system for the same | DR. R. PFLEGER CHEMISCHE FABRIK GMBH (DE) | 1999-12-07 | — | — | US | claimed |
| EP-0513099-B1 | NOVEL VEHICLE GASES AND THEIR USE IN MEDICAL PREPARATIONS | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-10-13 | — | — | EP | claimed |
| EP-0856312-B1 | Use of trospium chloride for the manufacture of a medicament for the treatment of diseases of the bladder | PFLEGER R CHEM FAB (DE) | 1998-10-14 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0514415-B1 | NOVEL VEHICLE GAS MIXTURES AND THEIR USE IN MEDICAL PREPARATIONS | BOEHRINGER INGELHEIM KG (DE) | 1998-05-06 | — | — | EP | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |